A phase 3 multicenter open-label study of Brigatinib (AP26113) versus Crizotinib in patients with ALK-positive advanced lung cancer (#678)
Laufzeit: 01.01.2017 - 31.12.2017
imported
Kurzfassung
A phase 3, multicenter, open-label study of Brigatinib (AP26113) versus Crizotinib in patients with ALK-positive advanced lung cancer
